Prevalence estimates of use of cancer screening tests among American Indian/Alaska Native and non-Hispanic White adults resident in CHSDA counties—Behavioral Risk Factor Surveillance System, 2000–2006a
| |
NHW Totala |
AI/AN Totala |
Northern Plainsb |
Alaskac |
Southern Plainsd |
Pacific Coaste |
Eastf |
Southwestg |
| %h |
(95% CI) |
% |
(95% CI) |
% |
(95% CI) |
% |
(95% CI) |
% |
(95% CI) |
% |
(95% CI) |
% |
(95% CI) |
% |
(95% CI) |
| Mammography within 2 years, women aged 40+i |
| |
76.0 |
(75.5–76.5) |
68.7 |
(64.7–72.4) |
73.9 |
(67.8–79.3) |
75.9 |
(69.6–81.2) |
71.3 |
(66.2–76.0) |
63.3 |
(52.3–73.1) |
70.7 |
(59.7–79.7) |
65.0 |
(58.4–71.0) |
| Papanicolaou (Pap) test within 3 years, women without hysterectomyi |
| |
83.7 |
(83.3–84.1) |
79.3 |
(76.4–82.0) |
83.3 |
(79.1–86.8) |
87.5 |
(84.5–90.1) |
77.7 |
(73.7–81.3) |
76.4 |
(69.1–82.4) |
74.9 |
(64.7–82.9) |
80.1 |
(76.4–83.4) |
| Prostate specific antigen test within 1 year, men aged 50–75j |
| |
53.0 |
(52.3–53.6) |
44.4 |
(39.2–49.7) |
50.0 |
(42.4–57.6) |
34.8 |
(27.8–42.5) |
45.4 |
(40.1–50.7) |
45.4 |
(35.2–56.1) |
43.4 |
(34.0–53.4) |
41.6 |
(35.9–47.5) |
| Fecal occult blood test within 1 year or endoscopy within 5 years, aged 50+j |
| All |
54.3 |
(53.8–54.8) |
40.2 |
(35.5–45.0) |
36.0 |
(29.1–43.5) |
49.4 |
(42.8–56.1) |
42.4 |
(38.1–46.9) |
41.1 |
(31.5–51.5) |
41.3 |
(32.5–50.7) |
33.8 |
(28.8–39.1) |
| Male |
56.0 |
(55.2–56.8) |
39.6 |
(32.7–47.0) |
26.0 |
(18.4–35.4) |
42.9 |
(33.6–52.6) |
46.4 |
(39.5–53.5) |
45.9 |
(32.3–60.2) |
29.8 |
(19.9–42.1) |
33.6 |
(26.1–42.0) |
| Female |
53.1 |
(52.4–53.8) |
41.4 |
(35.9–47.1) |
45.2 |
(36.2–54.6) |
55.1 |
(46.0–63.8) |
38.8 |
(33.6–44.3) |
40.0 |
(27.8–53.6) |
53.5 |
(41.7–64.9) |
33.9 |
(27.6–40.8) |
CHSDA indicates Contract Health Service Delivery Areas of the Indian Health Service; NHW, non-Hispanic whites; AI/AN, American Indians/Alaska Natives; 95% CI, 95% confidence interval.
a Data from 33 U.S. states (includes states listed in the footnotes below).
b AI/AN in Indiana, Iowa, Michigan, Minnesota, Montana, Nebraska, North Dakota, South Dakota, Wisconsin, and Wyoming.
c AI/AN in Alaska.
d AI/AN in Kansas, Oklahoma, and Texas.
e AI/AN in California, Idaho, Oregon, and Washington.
f AI/AN in Alabama, Connecticut, Florida, Louisiana, Maine, Massachusetts, Mississippi, New York, North Carolina, Rhode Island, and South Carolina.
g AI/AN in Arizona, Colorado, Nevada, New Mexico, and Utah.
h All prevalence estimates are weighted and age-adjusted to the 2000 US standard population. "Refused" and "don’t know" responses are excluded.
i 2000, 2002, 2004, and 2006 (AI/AN estimates do not include Massachusetts).
j 2001, 2002, 2004, and 2006 (AI/AN estimates do not include Massachusetts).
Download table formatted for print (PDF-36KB)
Please note: Some of these publications are available for download only as *.pdf files. These files require Adobe Acrobat Reader in order to be viewed. Please review the information on downloading and using Acrobat Reader software.
Page last reviewed: August 22, 2008
Page last updated: August 22, 2008
Content source: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention
